Lesueur F, Truong T (2022) Genetic susceptibility to differentiated thyroid cancer. IntechOpen

Matrone A, Campopiano MC, Nervo A, Sapuppo G, Tavarelli M, De Leo S (2019) Differentiated thyroid cancer, from active surveillance to advanced therapy: toward a personalized medicine. Front Endocrinol (Lausanne) 10:884

Article  PubMed  Google Scholar 

Paschke R, Lincke T, Müller SP, Kreissl MC, Dralle H, Fassnacht M (2015) The treatment of well-differentiated thyroid carcinoma. Dtsch Arztebl Int 112:452–458

PubMed  PubMed Central  Google Scholar 

Worden F (2014) Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther Adv Med Oncol 6:267–279

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmidt A, Iglesias L, Klain M, Pitoia F, Schlumberger MJ (2017) Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation. Arch Endocrinol Metab 61:81–89

Article  PubMed  PubMed Central  Google Scholar 

Faugeras L, Pirson AS, Donckier J et al (2018) Refractory thyroid carcinoma: which systemic treatment to use? Ther Adv Med Oncol 10:1758834017752853

Article  PubMed  PubMed Central  Google Scholar 

Aashiq M, Silverman DA, Na’ara S, Takahashi H, Amit M (2019) Radioiodine-refractory thyroid cancer: molecular basis of redifferentiation therapies, management, and novel therapies. Cancers (Basel) 11:1382

Article  CAS  PubMed  PubMed Central  Google Scholar 

Volpe F, Nappi C, Zampella E et al (2024) Current advances in radioactive iodine-refractory differentiated thyroid cancer. Curr Oncol 31:3870–3884

Article  PubMed  PubMed Central  Google Scholar 

Rulten SL, Grose RP, Gatz SA, Jones JL, Cameron AJM (2023) The future of precision oncology. Int J Mol Sci 24:12613

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chia S, Low JL, Zhang X et al (2017) Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nat Commun 8:435

Article  PubMed  PubMed Central  Google Scholar 

Floridi C, Cellina M, Irmici G et al (2022) Precision imaging guidance in the era of precision oncology: an update of imaging tools for interventional procedures. J Clin Med 11:4028

Article  PubMed  PubMed Central  Google Scholar 

Cortas C, Charalambous H (2023) Tyrosine kinase inhibitors for radioactive iodine refractory differentiated thyroid cancer. Life (Basel) 14:22

PubMed  PubMed Central  Google Scholar 

Zschäbitz S, Grüllich C (2018) Lenvantinib: a tyrosine kinase inhibitor of VEGFR 1–3, FGFR 1–4, PDGFRα, KIT and RET. Recent Results Cancer Res 211:187–198

Article  PubMed  Google Scholar 

Pitoia F, Jerkovich F, Trimboli P, Smulever A (2022) New approaches for patients with advanced radioiodine-refractory thyroid cancer. World J Clin Oncol 13:9–27

Article  PubMed  PubMed Central  Google Scholar 

Fleeman N, Houten R, Chaplin M et al (2019) A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC Cancer 19:1209

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herranz UA (2022) Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer. Cancer Med 11(Suppl 1):47–53

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jasim S, Ozsari L, Habra MA (2014) Multikinase inhibitors use in differentiated thyroid carcinoma. Biologics 8:281–291

PubMed  PubMed Central  Google Scholar 

Haddad RI, Schlumberger M, Wirth LJ et al (2017) Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine 56:121–128

Article  CAS  PubMed  PubMed Central  Google Scholar 

Subbiah V, Hu MI, Mansfield AS et al (2024) Pralsetinib in patients with advanced/metastatic rearranged during transfection (RET)-Altered thyroid cancer: Updated efficacy and safety data from the ARROW Study. Thyroid 34:26–40

Article  PubMed  Google Scholar 

Jozaghi Y, Zafereo M, Williams MD et al (2021) Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck 43:E7-e12

Article  PubMed  Google Scholar 

Satapathy S, Bal C (2022) Theranostic options for radioiodine-refractory differentiated thyroid carcinoma: recent advances, challenges, and road ahead. Front Endocrinol (Lausanne) 13:924841

Article  PubMed  PubMed Central  Google Scholar 

Taunk NK, Escorcia FE, Lewis JS, Bodei L (2024) Radiopharmaceuticals for cancer diagnosis and therapy: new targets, new therapies-alpha-emitters, novel targets. Cancer J 30:218–223

Article  CAS  PubMed  PubMed Central  Google Scholar 

Watabe T, Hirata K, Iima M et al (2025) Recent advances in theranostics and oncology PET: emerging radionuclides and targets. Ann Nucl Med 39:909–921

Article  PubMed  PubMed Central  Google Scholar 

Oh JM, Ahn BC (2021) Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. Theranostics 11:6251–6277

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buffet C, Wassermann J, Hecht F et al (2020) Redifferentiation of radioiodine-refractory thyroid cancers. Endocrine-Related Cancer 27:113–132

Article  Google Scholar 

Chung J-K, Cheon GJ (2014) Radioiodine therapy in differentiated thyroid cancer: The first target ed therapy in oncology. Endocrinol Metab 29:233

Article  Google Scholar 

Yao C, Pan YI, Li Y et al (2015) Effect of sodium/iodide symporter (NIS)-mediated radioiodine therapy o n estrogen receptor-negative breast cancer. Oncol Rep 34:59–66

Article  CAS  PubMed  Google Scholar 

Liu D, Hou P, Liu Z, Wu G, Xing M (2009) Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 69:7311–7319

Article  CAS  PubMed  PubMed Central  Google Scholar 

Landa I, Ganly I, Chan TA et al (2013) Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 98:E1562-1566

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nichols JM, Antolović V, Reich JD, Brameyer S, Paschke P, Chubb JR (2020) Cell and molecular transitions during efficient dedifferentiation. Elife 9:e55435

Article  PubMed  PubMed Central  Google Scholar 

Petranović Ovčariček P, Tuncel M, Aghaee A, Campennì A, Giovanella L (2024) Redifferentiation therapies in thyroid oncology: molecular and clinical aspects. J Clin Med 13:7021

Article  Google Scholar 

Ho AL, Grewal RK, Leboeuf R et al (2013) Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 368:623–632

Article  CAS  PubMed  PubMed Central  Google Scholar 

Larson SM, Osborne JR, Grewal RK, Tuttle RM (2017) Redifferentiating thyroid cancer: selumetinib-enhanced radioiodine uptake in thyroid cancer. Mol Imaging Radionucl Ther 26:80–86